CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard first-line treatment for patients with PD-L1 combined positive score (CPS) ≥5. Sugemalimab is the first anti-PD-L1 monoclonal antibody demonstrating superior overall survival (OS) and progression free...
Lessons from Japan’s AMR Response for the Global Community
https://iris.who.int/handle/10665/380481 TOKYO, Feb. 25, 2025 /PRNewswire/ -- World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan's AMR Response 2013–2025 alongside Tokyo AMR One Health Conference (February 18–19, 2025), hosted by Ministry of Health Labour and Welfare, Japan and co-hosted by WPRO and WHO Regional Office for South-East Asia. Developed by the AMR Clinical...
Medtronic Malaysia and Malaysian Society of Colorectal Surgeons sign MOU to enhance medical training and education programs
KUALA LUMPUR, Malaysia, Feb. 25, 2025 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, announced that Medtronic Malaysia and Malaysian Society of Colorectal Surgeons (MSCRS) have signed a Memorandum of Understanding (MoU) to jointly organize surgical workshops aimed at enhancing the skills of colorectal surgeons in Malaysia. Dr Nurhashim Haron, Vice President of...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer’s ADCs
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs)...
AIM Vaccine’s mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the...
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics
REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research, utilizing untargeted metabolomic and lipidomic profiling, addresses a critical knowledge gap in ADHD treatment. It reveals a convergence...
LabConnect and Australian Clinical Labs’ Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region
PORT MELBOURNE, Australia and JOHNSON CITY, Tenn., Feb. 24, 2025 /PRNewswire/ -- LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Australia and the Asia-Pacific region. This exclusive, multi-year agreement solidifies the partnership, and enables both organizations to leverage complementary strengths...
Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy
TORONTO, Feb. 24, 2025 /PRNewswire/ -- In today's era of rapid technological advancement, the deep integration of artificial intelligence and the medical field is bringing unprecedented hope to human health. Among these advancements, targeted therapy, a cornerstone of precision medicine, is gradually reshaping the treatment landscape for cancer and other major diseases with its unique advantages. Visionary Holdings...
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resistant to IBZ, allowing regrowth of resistant microbes known to confer health benefits This study used in...
HKBU receives resounding support from Nobel Laureate and field experts in new medical school proposal and the establishment of translational medical research institute
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- The Preparatory Committee and Expert Advisory Committee for the New Medical School set up by Hong Kong Baptist University (HKBU) held a meeting yesterday (23 February), during which progress of the preparation of the University's new medical school proposal was discussed and unanimously supported by all the committee members. With the backing of 2020...
